Republicans in the House of Representatives this week laid out their alternative to the Affordable Care Act (ACA) in an effort to position themselves against various Democratic healthcare proposals. The document contains many ideas that have been debated previously when Republicans tried to repeal the ACA, and it draws on work from the Heritage Foundation and the Cato Institute.
Republicans in the House of Representatives this week laid out their alternative to the Affordable Care Act (ACA) in an effort to position themselves against various Democratic healthcare proposals.
The Republican Study Committee (RSC) called the plan “practical solutions to repair our broken healthcare system.” This first part of their plan lays out their vision should the Republicans regain the House of Representatives and should Donald Trump be reelected to the presidency in 2020.
The document contains many ideas that have been debated previously when Republicans tried to repeal the ACA, and it draws on work from the Heritage Foundation and the Cato Institute.
While the ACA contains many regulatory provisions and pathways such as the Biologics Price Competition and Innovation Act or BPCIA, and forms the Center for Medicare and Medicaid Innovation in CMS, this first part of the RSC plan is silent on those issues, though they may be discussed in the next release of the plan.
The RSC said a second report will follow, with additional recommendations “to further reduce the cost of healthcare and increased transparency competition and innovation technologies. This will include recommendation on policies like transparency competition in reducing barriers to technological innovation.”
Among other things, the plan released Tuesday addresses pre-existing conditions, access to primary care, health savings accounts (HSAs), and more.
While the plan retains protection for pre-existing conditions, it removes the ACA provision that kept insurers from charging patients with costly healthcare needs more money, through the introduction of high-risk pools. The plan calls these “guaranteed coverage pools” to be funded by the subsidies that previously went to exchange plans for those who qualified for help paying premiums, as well as ending and diverting Medicaid expansion funds.
The plan would end Medicaid expansion and replace Medicaid with a block grant; states that adopt a work requirement may be eligible for more funding. Republicans call this “rightsizing” Medicaid.
“There is no reason why an able-bodied adult without any dependents should be more heavily subsidized” than “a poor pregnant woman, elderly person, child, disabled individual, or parent,” the document states.
The blueprint also focuses heavily on HSAs. It increases the amount that an individual or family could contribute; the current limits are $3500 for an individual and $7000 for family. The RSC plan would increase those amounts to $9000 per individual and $18,000 for families.
In addition, the scope of eligible expenditures for HSAs would expand as they would be allowed to issue reimbursements for health insurance premiums. The RSC plan would also sever the rule that HSAs be linked to a high-deductible health plan.
It also champions short-term healthcare plans and association healthcare plans, as well as “healthcare sharing ministries,” in which people with a common set of beliefs pool their money and share medical expenses among themselves. Under such an arrangement, those pulling the money could decide what they will and will not pay for—such as reproductive health care.
Another model backed by Republicans is the direct primary care model, in which patients pay a monthly fee to a provider instead of an insurance copayment or coinsurance. The fee covers primary care services, clinical laboratory services, consultations, care coordination, and comprehensive care management.
The plan also recommends expanding access to telemedicine by ending state regulatory barriers.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.